

# 1 **Statistical analysis Plan**

2

3

## 4 **1. Database**

5 The development of the base will be managed by the West Clinical Research Unit (URC-  
6 Ouest). The clinical database will be developed in MySQL. This database can be filled in  
7 online through a site developed in APHP. Progress, entry and connection controls will be  
8 implemented, in addition to the usual security requirements. The statistical analysis will be  
9 managed in the INSERM UMR S707 unit. We will use R and SAS V9.1 software (SAS Institute).

### 10 ○ Statistical analysis

11 The baseline characteristics of the patients (age, sex, scores, etc.) will be described by mean,  
12 median, inter-quartile interval and standard deviation for continuous variables and by  
13 frequencies with a 95% confidence interval for the qualitative variables.

14 We will compare mortality rates between the two strategies by adjusting for severity,  
15 autonomy, chronic diseases and nutrition status. We will use a mixed logistic regression  
16 model.

17

18 The other analyzes will concern the secondary criteria. We will compare the rates of ICU  
19 admissions and their variability in the RSA group and the SP group (gross rates and ICC  
20 values). We will also analyze the survival of patients in both groups (Cox models). The quality  
21 of life and the "burden" of caregivers of patients living at home at six months will also be  
22 compared in each group.

23

24 In addition, we will assess the impact of the implementation of the study on all ICU  
25 admissions of elderly people from the emergency departments. And the impact of this  
26 possible "contamination" on the overall mortality observed in ICU and in the hospital.

27

28 Based on data from the CUB-Réa database, we will be able to assess the volume of elderly  
29 patients included in the participating centers, the hospital mortality and the in-ICU mortality  
30 of included patients in the two years preceding the study in order to detect any change  
31 during the implementation of the study, in each of the two groups (RSA / SP).

32 ○ Sample Size Calculation

33 Based on the results of the ICE-CUB 1 study, 32% of patients die within six months of the  
34 emergency department visit. We hypothesize that the mortality of patients over 75 years of  
35 age will be equivalent and that the proposed intervention will reduce mortality by 6% at six  
36 months. In a unilateral situation, with a type one error rate of 5%, without taking into  
37 account the cluster effect, 704 patients per group are necessary to demonstrate such a  
38 difference with a power of 80%. Cluster randomization imposes inflation dependent on  
39 intraclass correlation coefficient (ICC). With an ICC at 0.01, an average of 100 patients per  
40 center, a total of 2802 patients are required.

41  
42 Based on the data from the ICE-CUB 1 study, 560 patients over 80 years of age with factors  
43 of good prognostic and a critical conditions requiring organ support were admitted to the  
44 emergency department of 15 centers over a 1-year period. It is assumed that  $560 * 1.5 = 840$   
45 patients over the age of 75 with the same characteristics, with an average of 56 patients per  
46 center per year. Thus, it is estimated that the number of subjects needed ( $n=2802$ ) can be  
47 reached in 2 years with 20 participating centers.

48 ○ Management of the missing, unused or invalid data

49 The management of the missing data will be carried out according to the complexity and  
50 the frequency of the situations. The MCAR or MAR character will be evaluated according to  
51 the Little & Rubin classification (Statistical Analysis with Missing data, Wiley 1987). If the  
52 proportion of missing data is less than 0.05, a simple imputation will be used, otherwise a  
53 multiple imputation will be performed. A sensitivity analysis will be carried out if the  
54 proportion is very high.

55 ○ Management of modifications to the initial strategy analysis plan

56 Changes in statistical methods decided retrospectively and validated by the steering  
57 committee will be presented in an amendment to the protocol and in the analysis report of  
58 the study.

59 - Access to data and source documents

60 Persons with direct access in accordance with the applicable laws and regulations, in  
61 particular Articles L.1121-3 and R.5121-13 of the Public Health Code (investigators, quality  
62 control persons, monitors, clinical research assistants, auditors and others involved in

63 research) shall take all necessary precautions to ensure the confidentiality of information  
64 relating to investigational medicinal products, tests, appropriate persons and particularly as  
65 regards their identity and the results obtained. The data collected by these persons during  
66 the quality control or audits are then made anonymous.

67 - Quality Control and Quality Assurance

68 The search will be conducted according to the sponsor standard operating procedures.

69 The conduct of the research in the investigating centers and the management of the subjects  
70 will be done in accordance with the Helsinki Declaration and the Good Practices in force.

71 ○ Monitoring Procedures

72 Risk level of the study: the Clinical Research Assistants (CRA) representative of the sponsor  
73 will visit the investigating centers at the rate corresponding to the follow-up of the patients  
74 in the research protocol, to the inclusions in the different centers and to the level of risk that  
75 has been attributed to the research.

76 - Opening visit of each center: before inclusion, for the implementation of the protocol and  
77 acquaintance with the various participants in the research.

78 The principal investigator of each center as well as the other investigators including or  
79 following included patients involved in the research are engaged to receive the CRAs at  
80 regular intervals.

81 During these on-site visits and in accordance with the Good Clinical Practices, the following  
82 elements will be reviewed:

83 Compliance with protocol and defined procedures for research,

84 Verification of informed consent of patient

85 Review of source documents and comparison with data reported in the observation booklet  
86 as to accuracy, missing data, consistency of data according to the rules laid down by DRCD  
87 procedures.

88 Closure visit: retrieval of research documents, archiving.

89 ○ Transcription of the data in the observation booklet

90 The CRF will be developed by Clinical Research Unit (URC) Ouest in collaboration with the  
91 Study Coordinator. The data of the research will be entered directly by the participating  
92 physicians by means of a form accessible online or transcribed from the observation books  
93 by the Clinical Study Technicians (TEC) recruited and managed by the URC-EST for the  
94 centers of Ile-de-France and by the TEC of the centers in the provinces. These data will be  
95 centralized on a server of the University of Versailles Saint-Quentin.

96 The data management will be carried out by the Clinical Research Unit Ouest (URC Ouest).

97 All information required by the protocol must be provided in the CRF and an explanation  
98 given by the investigator for each missing data.

99 Clinical or para-clinical data should be transferred to the e.CRF as they are obtained.

100 The erroneous data detected on the e.CRF will be corrected by an investigator, who will have  
101 connected to the software with its access codes (username and password). These codes are  
102 strictly personal and confidential and are not disseminated to any third party; They help  
103 ensure data confidentiality and authenticate interventions. The access codes are associated  
104 with an electronic signature system which validates the data entered by the investigator.  
105 Each signature is time stamped and recorded in the audit trail of the search. The signed data  
106 cannot be modified, but the investigator can cancel his signature if he wants to correct a  
107 data. The cancellation of the signature is also subject to time-stamped recording.

108 The anonymity of the patients will be ensured by the maximum use of the numbers, the first  
109 letters of the surname and first name of the patient, on all the documents necessary for the  
110 research, or erasure by the appropriate means of the nominal data on the copies of the  
111 source documents, intended for the documentation of the search.

112 The file of the computerized data will be declared to the CNIL according to the procedure  
113 adapted to the case.

114 ○ Completeness of the inclusions

115 In order to assess the completeness of the inclusions, an audit will be carried out by  
116 randomly drawing one week in each center. A TEC and an investigating physician will visit

117 each center to assess the number of patients not included in this week by reviewing the  
118 emergency registry.

119

120

121